How does 0RKT's PS Ratio compare to its peers?

0RKT is expensive based on its Price-To-Sales Ratio (9.9x) compared to the peer average (5.2x).

How does 0RKT's PS Ratio compare vs other companies in the European Life Sciences Industry?

0RKT is expensive based on its Price-To-Sales Ratio (9.9x) compared to the European Life Sciences industry average (4.3x).

What is 0RKT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 0RKT's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of 0RKT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 0RKT's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

0RKT Stock Overview

A biotechnology company, engages in developing of small molecule therapies for treatment in oncology in Poland, rest of the European Union, and internationally. More details

0RKT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 19.3% per year

Risk Analysis

Earnings are forecast to decline by an average of 10.1% per year for the next 3 years

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

My Notes

Capture your thoughts, links and company narrative

Ryvu Therapeutics S.A. Competitors

hVIVO

AIM:HVO

UK£133.7m

Diaceutics

AIM:DXRX

UK£106.0m

MaxCyte

AIM:MXCT

UK£348.8m

Ergomed

AIM:ERGO

UK£701.1m

Price History & Performance

Summary of share price highs, lows and changes for Ryvu Therapeutics
Historical stock prices
Current Share Price	zł36.50
52 Week High	zł36.50
52 Week Low	zł36.50
Beta	0.65
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-31.78%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	0RKT	GB Life Sciences	GB Market
7D	n/a	-6.8%	-2.2%
1Y	n/a	-26.2%	2.4%

Return vs Industry: Insufficient data to determine how 0RKT performed against the UK Life Sciences industry.

Return vs Market: Insufficient data to determine how 0RKT performed against the UK Market.

Price Volatility

Is 0RKT's price volatile compared to industry and market?
0RKT volatility
0RKT Average Weekly Movement	n/a
Life Sciences Industry Average Movement	7.3%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.5%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0RKT's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0RKT's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	270	Pawel Przewiezlikowski	ryvu.com

Ryvu Therapeutics S.A., a biotechnology company, engages in developing of small molecule therapies for treatment in oncology in Poland, rest of the European Union, and internationally. Its lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat hematological malignancies, solid tumors, acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis. The company also develops SEL24/MEN1703, a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia.

Ryvu Therapeutics S.A. Fundamentals Summary

How do Ryvu Therapeutics's earnings and revenue compare to its market cap?
0RKT fundamental statistics
Market cap	zł913.25m
Earnings (TTM)	-zł104.14m
Revenue (TTM)	zł91.18m

9.9x

P/S Ratio

-8.7x

P/E Ratio

Is 0RKT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RKT income statement (TTM)
Revenue	zł91.18m
Cost of Revenue	zł18.68m
Gross Profit	zł72.50m
Other Expenses	zł176.63m
Earnings	-zł104.14m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-4.50
Gross Margin	79.51%
Net Profit Margin	-114.21%
Debt/Equity Ratio	45.3%

How did 0RKT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 21:01
End of Day Share Price	2024/12/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ryvu Therapeutics S.A. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kamil Kliszcz	Biuro maklerskie mBanku
Beata Szparaga-Wasniewska	Biuro maklerskie mBanku
Jonas Peciulis	Edison Investment Research